Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.80, $0.40 better than the analyst estimate of $2.40. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.

GUIDANCE:

Charles River Laboratories sees FY2024 EPS of $9.90-$10.20, versus the consensus of $10.99.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.